To evaluate the efficacy of first-line bevacizumab-based chemotherapy for untreated metastatic colorectal cancer (mCRC) based on age. Methods: Eligibility criteria focused on M1 disease without prior palliative chemotherapy. Choice of chemotherapy regimen was at the physician’s discretion.
Hofheinz et al BMC Cancer 2014, 14:761 http://www.biomedcentral.com/1471-2407/14/761 RESEARCH ARTICLE Open Access Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results Ralf Hofheinz1*, Volker Petersen2, Manfred Kindler3, Mathias Schulze4, Joerg Seraphin5, Heinz-Gert Hoeffkes6, Anette-R Valdix7, Jan Schroeder8, Julia Herrenberger9, Alexander Stein10, Axel Hinke11 and Dirk Arnold12 Abstract Background: To evaluate the efficacy of first-line bevacizumab-based chemotherapy for untreated metastatic colorectal cancer (mCRC) based on age Methods: Eligibility criteria focused on M1 disease without prior palliative chemotherapy Choice of chemotherapy regimen was at the physician’s discretion Predefined efficacy endpoints were response rate, progression-free and overall survival (PFS, OS) Patients were analysed by age (